Adverum Biotechnologies Reveals 26-Week Interim Analysis Results Of Ixo-vec From LUNA Phase 2 Trial At 2024 ASRS Annual Meeting
$ADVM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks
- Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control
- Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis
- Patient Preference Survey: 88% of patients indicated a preference for Ixo-vec over their prior anti-VEGF injections, and 93% would opt to receive Ixo-vec in the other eye
- Efficacy and safety with 6E10 at 26-weeks similar to or better than in OPTIC at 2E11, where clinical benefit was demonstrated beyond 3 years
- LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024